Glycomics, Natural drug discovery, Immunology, Regenerative medicine
Biotechnology capabilities extend across a broad range of drug, vaccine and diagnostic discoveries utilising a multi-disciplinary approach at the Institute of Glycomics, a natural drug discovery focus at the Griffith Institute of Drug Discovery (GRIDD); and Immunology and Regenerative Medicine specialisations within Griffith’s Menzies Health Institute Queensland (MHIQ).
Unique in Australia and globally collaborative, the Institute for Glycomics pioneers the study of glycans (sugars coating cells) in disease processes, for cancer and infectious diseases. With more than 200 researchers, the Institute’s technologies tackle diseases of global impact, and include a world-first whole-of-parasite malaria vaccine candidate known as PlasProtect® in human clinical trials, and a Group A Streptococcus vaccine in co-development with Chinese company Olymvax Biopharmaceuticals.
Innovating at the cutting-edge of chemistry and biology and boasting the unique resources of NatureBank and Compounds Australia, GRIDD researchers, including the Centre for Cell Factories and Biopolymers, apply novel approaches together with global partners.
MHIQ undertakes research across the lifecycle to identify key factors that influence health with biomedical research focused on infectious diseases and immunology, chronic disease and ageing and regenerative and rehabilitation medicine.